Michael James Newman is CSO & Director at Indaptus Therapeutics, Inc. (INDP). They have made 1 open-market trade across 1 company since 2022, most recently 2025-12-22.
CIK 0001876315
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| INDP | 101,074 | $278K |
Shares reported on the most recent Form 4, priced at the 2025-12-29 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| INDP | SELL | 2022-01-31 | 2022-02-02 | $5.00 | $100K | +8.1% | -9.2% | -32.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.